Bradley Sitko Acquires 4,134 Shares of XOMA Co. (NASDAQ:XOMA) Stock

XOMA Co. (NASDAQ:XOMA) CIO Bradley Sitko bought 4,134 shares of the business’s stock in a transaction dated Friday, March 21st. The shares were bought at an average cost of $23.89 per share, for a total transaction of $98,761.26. Following the transaction, the executive now owns 10,484 shares in the company, valued at approximately $250,462.76. The trade was a 65.10 % increase in their position. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website.

Bradley Sitko also recently made the following trade(s):

• On Wednesday, January 8th, Bradley Sitko acquired 313 shares of XOMA stock. The shares were purchased at an average cost of $25.60 per share, with a total value of $8,012.80.
• On Tuesday, December 31st, Bradley Sitko purchased 300 shares of XOMA stock. The shares were purchased at an average price of $25.90 per share, for a total transaction of $7,770.00.

XOMA Trading Down 0.9 %

Shares of XOMA opened at $20.74 on Wednesday. The firm has a market capitalization of $248.44 million, a price-to-earnings ratio of -5.96 and a beta of 1.00. The company has a 50-day moving average of $24.16 and a 200 day moving average of $27.03. XOMA Co. has a 1-year low of $19.92 and a 1-year high of $35.00. The company has a debt-to-equity ratio of 1.28, a current ratio of 7.52 and a quick ratio of 7.52.

XOMA (NASDAQ:XOMA) last announced its quarterly earnings data on Monday, March 17th. The biotechnology company reported ($0.46) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.29) by ($0.17). XOMA had a negative return on equity of 24.95% and a negative net margin of 151.34%. The firm had revenue of $8.70 million during the quarter, compared to the consensus estimate of $8.75 million. On average, research analysts expect that XOMA Co. will post -1.41 EPS for the current year.

Analyst Ratings Changes

XOMA has been the subject of several recent analyst reports. StockNews.com upgraded XOMA from a “sell” rating to a “hold” rating in a research report on Friday, March 21st. HC Wainwright restated a “buy” rating and set a $104.00 price objective on shares of XOMA in a report on Wednesday, March 19th.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently added to or reduced their stakes in the business. BNP Paribas Financial Markets boosted its stake in shares of XOMA by 95.0% during the third quarter. BNP Paribas Financial Markets now owns 1,632 shares of the biotechnology company’s stock valued at $43,000 after purchasing an additional 795 shares in the last quarter. New York State Common Retirement Fund lifted its holdings in XOMA by 51.2% during the fourth quarter. New York State Common Retirement Fund now owns 2,362 shares of the biotechnology company’s stock worth $62,000 after buying an additional 800 shares during the period. Wells Fargo & Company MN lifted its holdings in XOMA by 38.0% during the fourth quarter. Wells Fargo & Company MN now owns 4,300 shares of the biotechnology company’s stock worth $113,000 after buying an additional 1,183 shares during the period. Bank of America Corp DE boosted its position in XOMA by 34.7% during the 4th quarter. Bank of America Corp DE now owns 7,796 shares of the biotechnology company’s stock valued at $205,000 after acquiring an additional 2,009 shares in the last quarter. Finally, Los Angeles Capital Management LLC purchased a new position in shares of XOMA in the 4th quarter valued at $206,000. 95.92% of the stock is currently owned by institutional investors.

XOMA Company Profile

XOMA Corporation operates as a biotech royalty aggregator in the United States and the Asia Pacific. It has a portfolio of economic rights to future potential milestone and royalty payments associated with partnered commercial and pre-commercial therapeutic candidates. The company also focuses on early to mid-stage clinical assets primarily in Phase 1 and 2 with commercial sales potential that are licensed to partners; and acquires milestone and royalty revenue streams on late-stage clinical or commercial assets.